Sputum quantitative culture, acid-fast smear, days-to-positive by BACTEC, and Mycobacterium tuberculosis antigen 85 complex were monitored during therapy in 42 patients with pulmonary tuberculosis (TB). By BACTEC, 4 patients were persistently positive on days 90 -180, and treatment ultimately failed in 2 of these. Antigen 85 expression increased in subjects in whom disease persisted (persisters) from days 0 to 14 when the difference between persisters and nonpersisters was statistically significant (P Å .002). Only antigen 85 complex values at day 14 suggested TB persistence at or after day 90. All subjects with day 14 antigen 85 complex values õ60 pg/mL responded rapidly to treatment and were cured. Of those with values ú60 pg/mL, in 33% TB persisted at or after day 90 and treatment failed in 17%. Biologic factors expressed early in therapy, not related to compliance or resistance, may exert a substantial influence on outcome. The antigen 85 complex is critical in cell wall biosynthesis and is induced by isoniazid in vitro. Its induction may represent an adaptive transition to a persistent state during therapy.
Mycobacterium tuberculosis has a remarkable ability to persputum (as days to positive in mycobacterial growth indicator tube [MGIT] cultures) during therapy predicted outcome in sist under adverse conditions, often resisting both the host immune response and prolonged combination chemotherapy. Myindividual patients [4] . In that study, all 13 in whom treatment failed but none of 13 who were cured had §1 positive MGIT cobacterial survival in conditions of low oxygen tension is enhanced by induction and accumulation of the heat-shock culture within 20 days by day 40 of therapy. These reports suggest it may be possible to use early markers to individualize protein a-crystallin in the cell wall [1, 2] . The mechanisms involved in persistence during therapy are less well understood, TB therapy, potentially offering superior outcomes and greater efficiency in resource utilization. as there are no satisfactory models to study this phenomenon in vitro. However, it is generally believed that most actively
In the present study, sputum log 10 M. tuberculosis colonyforming units (cfu) and quantitative microscopy (acid-fast bareplicating bacilli are killed early in therapy and that prolonged treatment is required to eradicate persisting organisms exhibcilli [AFB]), days-to-positive (DTP) by BACTEC, and antigen 85 complex expression were evaluated prospectively during iting reduced or altered metabolism. As a consequence, tuberculosis (TB) therapy is more prolonged and more complex than early multidrug therapy of smear-positive pulmonary TB. The antigen 85 complex comprises 3 30-to 32-kDa related proteins that of nearly all other infections.
Several studies have suggested that the kinetics of the early that are mainly localized to the extracellular space during in vitro growth of M. tuberculosis and are secreted in an energyresponse to TB therapy provide important clues regarding the likelihood of relapse. By meta-analysis, Mitchison [3] found dependent process involving an upstream signal sequence [5, 6] . The proteins, mycolyl transferases, are essential for cell that regimens with superior sterilizing activity at 1 -2 months of treatment had lower relapse rates [3] . Epstein et al. [4] wall biosynthesis [7] . Expression of the antigen 85 complex is induced by isoniazid in what has been interpreted as a response reported that quantitative assessment of viable mycobacteria in by damaged mycobacteria to maintain the integrity of a partially compromised cell wall [8] . Thus, analysis of antigen 85 expression during therapy might provide insights into mecha-HIV-1 was done for all subjects; those identified as HIV-1 seroposmL of a 1:1 mixture of 4% NaOH and 2.9% sodium citrate for 15 min. The specimen was then washed by addition of 45 mL of itive were excluded from further study. Subjects were also excluded from this analysis if their isolates were identified as resistant phosphate buffer. Bacilli were sedimented, diluted serially in 0.25% Tween-80 (Sigma, St. Louis) in 0.9% NaCl, and plated on to isoniazid, rifampin, pyrazinamide, or ethambutol or they were followed õ180 days.
Middlebrook Cohn 7H10 agar medium, placed in BACTEC culture, and examined by acid-fast microscopy. Even though deconRadiographic extent of disease. The radiographic extent of disease was classified in accordance with National Tuberculosis tamination of sputum with NaOH reduces cfu by 80% [10] , we used this method because, in a pilot study, NaOH resulted in and Respiratory Disease Association criteria [9] into one of three categories: minimal, moderately advanced, or far advanced disless contamination than did an antibiotic-containing medium and because the reduction in cfu levels due to use of NaOH was consisease. In persons with minimal disease, lesions are noncavitary with slight-to-moderate density and involve a small area of one or both tent among specimens. 85 ELISA. Culture filtrate of M. tuberculosis H37Rv was lungs (total extent is less than the volume of one lung above the second chondrosternal junction and the spine of the fourth or body prepared from spent Proskauer-Beck medium as previously described [11] . The antigen 85 complex represented 10% of the of the fifth thoracic vertebrae). In persons with moderately advanced disease, slight to moderately dense lesions occupy a total protein content of the filtrate by densitometry and Western blot analysis with monoclonal antibody TBC-27 [12] ; this antibody volume of one lung or less and dense lesions are less than one-third the volume of one lung; cavitary lesions are õ4 cm in diameter. In was also used for antigen capture. TBC-27 was purified from hybridoma cells grown in serum-free medium, biotinylated usfar advanced disease, lesions are more extensive than in moderately advanced disease.
ing sulfo-N-hydroxysuccinimide biotin (Pierce, Rockford, IL), and fixed to avidin-precoated plates (Pierce). Nonspecific proAfter collection of baseline specimens, subjects were treated daily with isoniazid, rifampin, ethambutol, and pyrazinamide at tein binding was inhibited with Superblock (Pierce). Samples were diluted in an equal volume of Superblock, added to single standard doses for 2 months and then with isoniazid and rifampin daily for 4 months. Patients were hospitalized for the initial 2 ELISA wells, and incubated overnight. Antigen was detected using rabbit bacille Calmette-Guérin antiserum (Dako, Carpintweeks of treatment to facilitate frequent sputum collection. During that time, therapy was directly observed. Thereafter, therapy was eria, CA) that had been preabsorbed using a column of immobilized TBC-27. Bound rabbit immunoglobulin was detected with self-administered. Compliance was assessed by review of dispensing records, clinic attendance, and by urinary isoniazid metabolite alkaline phosphatase -conjugated anti-rabbit immunoglobulin (Pierce). After being washed, the alkaline phosphatase signal testing. Subjects were classified as having treatment failure or relapse if M. tuberculosis was repeatedly identified on days 120-was amplified by a recycling NADH method described by Self [13] . Amplifier (0.02 mM NAPD / in 50 mM diethanolamine, 1 180 or after day 180, respectively, in conjunction with symptoms and radiographic findings consistent with active TB.
mM MgCl 2 , 0.1 mM ZnCl 2 , 15 mM NaN 3 , pH 9.5) was added to each well. After 10 min, a diaphorase-dehydrogenase mixture Specimen processing. Three sputum specimens were obtained prior to initiation of therapy. Two specimens were obtained on was added (2 mg/mL alcohol dehydrogenase, 1.5 mg/mL diaphorase, ethanol 4%, 0.55 mM p-iodonitrotetrazolium violet, and days 2, 4, 7, 14, 30, and monthly thereafter. Specimens were digested at room temperature for 1 min with 1 mL (25 mg/mL) of 5 mg/mL bovine serum albumin, pH 7.2). OD at 492 nm was determined after an additional 5 min. The results from the speci-N-acetyl cysteine (NALC) in phosphate buffer (pH 6.8). Specimens were vortexed with several 4-mm glass beads. An aliquot of 0.25 mens were compared to those of a serially diluted standard at 1 -1000 pg/mL, using four-parameter analysis (Softmax; MomL was removed and frozen for antigen analysis. A 2.5-mL aliquot of the remaining specimen was decontaminated by addition of 2.5 lecular Devices, Menlo Park, CA). The calculated values were tence is shown in figure 2. for DTP or cfu, respectively. Zero values and negative cultures were excluded in calculations of the coefficient of variation (SD/ mean). The correlation between variables was measured using the Pearson product method. Logistic regression was done using SigmaStat (SPSS, Chicago).
Results

Test characteristics.
A Western blot of M. tuberculosis culture filtrate using the capture monoclonal antibody TBC-27 is shown in figure 1 . The lower band represents 85B; 85A and C are in the upper band. Recognition of A, B, and C by TBC-27 was confirmed by 2-D Western blot (not shown). Figure 1 also shows a typical standard curve of the assay. The detection threshold of the assay was 2 -10 pg/mL. The coefficient of variation of duplicate wells of M. tuberculosis filtrate was 1% -5%.
Distribution of persistent TB and treatment failure. Fortytwo subjects were studied (21 in Brazil, 21 in Uganda) with follow-up of 308 { 70 days (mean { SD). The baseline characteristics of the subjects are described in table 1. Brazilian subjects were older and had more advanced disease by chest radiography but did not differ by any microbiologic parameter.
The duration of TB persistence was defined as the last day during therapy in which BACTEC cultures became positive in NOTE. AFB, acid-fast bacilli (mL); cfu, colony-forming units (mL); DTP, days to positive; antigen 85 (pg/mL); C, contaminated; NG, no growth. Specimens leading to classification of subjects as having persistent disease are shown in bold.
Two treatment failures were identified, 1 at each site. The .0001), but none of these parameters correlated with pretreatment antigen 85 complex scores (P Å .1 -.3). The cfu were overall treatment failure rate was 4.8%, but it was 50% (2/4) in subjects who were positive at or after day 90 versus 0/36 0.45 log 10 U lower than corresponding AFB scores (P õ .0001), in part reflecting the loss of viability due to proin all other subjects (P Å .007). Both patients with failed treatment were culture-and smear-negative for §2 months in cessing with NaOH for bacterial decontamination. The mean coefficients of variation of antigen 85 complex, cfu, AFB, midtherapy but became positive late in therapy (table 2) . In subject 29, failure was attributed to complete noncompliance and DTP in multiple specimens obtained on the same day from the same subject were 72%, 16%, 14%, and 24%, reduring the last 2 months of therapy. The other subject (80730) appeared to have reduced compliance during this time as evispectively. The large coefficients of variation of the antigen 85 ELISA may reflect the combined effects of sputum inhodenced by delayed clinic attendance; however, he had a positive urinary isoniazid metabolite test at each visit. In neither case mogeneity and small sample volume (100 mL). Changes during therapy. Cumulative expression of antiwas 1Њ or 2Њ drug resistance detected. The results of the cultures leading to the classification of the treatment failures as persisgen 85 during the first 30 days (estimated as area under the curve) was greater in subjects in whom TB persisted at or tent disease were not available until late in therapy (days 188 and 153). Thus, this parameter would not have been directly after day 90 than in all other subjects (P Å .005) ( figure 3 .006) and through day 7 for AFB and cfu (P õ .01). Such cated in table 2, high level antigen 85 expression recurred in this subject at the time that treatment failed. correlation over time within individuals is generally seen in most biologic processes.
Predicting persistence. Logistic regression analysis was performed to determine the extent to which day 7 -30 values Expression of antigen 85 complex increased significantly of all early markers predicted persistence to day 90 or beyond. from day 0 to days 7 and 14 only in the subjects in whom TB As indicated in table 3, a significant relationship was identified persisted (P Å .05). No significant increase from baseline was only for day 14 antigen 85 complex. A scatter plot of the observed in either group for any other parameter, although a relationship between outcome and day 14 85 complex is shown trend toward an increase was noted in AFB from days 0 -2 in those with persistent disease (P Å .067). The difference in antigen 85 expression between persisters and nonpersisters Table 3 . Univariate logistic regression analysis of the determinants reached P Å .002 by day 14. The difference did not appear to of TB persistence at or after day 90 during therapy.
be an artifact related to the small number of those with persis- Ugandan subjects, as these were equal on that day (P Å .15). The present study did not distinguish between cell wallassociated enzyme and that cleaved free of its signal peptide nor did it differentiate between the three members of the 85 complex. Some of the antigen detected may represent its accumulation on the cell wall as has been described with a-crys- localization, and molecular mechanisms for the increased protein expression observed in this study.
Our observations also raise questions regarding the potential in figure 4. All subjects with day 14 antigen 85 levels õ60 role of isoniazid in promoting persistence. Although isoniazid pg/mL (68% of the total) had clear cultures by day 90 and previously was considered to be bactericidal against M. tuberwere cured. Of the subjects with values ú60 pg/mL, 33%
culosis, that activity is markedly reduced when stationary-phase persisted positive at or after day 90 and for 17% therapy failed.
bacilli are studied [18, 19] or if the duration of culture is extended beyond a few days [20] . Mitchison and Nunn [21] concluded that isolated isoniazid resistance has little effect on Discussion clinical outcome in standard short-course TB therapy and that the sterilizing activity of isoniazid in vivo is substantially less TB is unique among chronic infections in that despite substantial interpatient variation, treatment is based on a standardthan that of rifampin and pyrazinamide. Isoniazid was antagonistic to the bactericidal activity of rifampin plus pyrazinamide ized regimen applied with little individual adjustment (directly observed short-course chemotherapy). Our study suggests that in two studies in mice [22, 23] . Although an adverse pharmacokinetic interaction between isoniazid and rifampin was identibiologic factors expressed early in therapy, not related to patient compliance or traditional measures of drug resistance, fied in the latter report, the authors noted that the magnitude of that interaction did not appear to be sufficient to explain the exert a substantial influence on outcome. Expression of the M. tuberculosis antigen 85 complex increased during the first 2 antagonism observed since blood levels of rifampin remained 80 times the MIC for M. tuberculosis [23] . Thus, further reweeks of therapy in subjects whose cultures persisted rapidly positive late in therapy. Ultimately, therapy failed in half of search is warranted to determine whether induction of enzymes for cell wall biosynthesis by isoniazid contributes to persistence this group. Its concentration on day 14 was the only predictor of persistence to day 90 or beyond. These observations have of disease and treatment failure during in human TB. Studies are also warranted to determine whether the observed intersubpractical implications for assessing patient responses to TB treatment and for more fundamental questions regarding mycoject variation in TB persistence is due to host or microbial factors. bacterial persistence.
The antigen 85 complex is essential for synthesis of trehalose From a practical perspective, early stratification of patients by sputum 85 complex may aid in the cost-efficient allocation dimycolate (cord factor), a glycolipid that defines many of the physical characteristics of the mycobacterial cell wall (includof resources in TB control programs and in the preliminary evaluation of new drugs. Future research might revisit detection ing acid fastness), and is a marker for virulence [7, 14, 15] . Isoniazid inhibits mycobacterial mycolic acid synthesis, in part of mycobacterial antigens in sputum for rapid TB diagnosis.
